Anti-CEAM1/ CEACAM1/ BGP monoclonal antibody
Anti-CEAM1/ CEACAM1/ BGP antibody for FACS & in-vivo assay
Go to CEACAM1/CEACAM1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T82105-Ab-1/ GM-Tg-hg-T82105-Ab-2 | Anti-Human CEACAM1 monoclonal antibody | Human |
GM-Tg-rg-T82105-Ab-1/ GM-Tg-rg-T82105-Ab-2 | Anti-Rat CEACAM1 monoclonal antibody | Rat |
GM-Tg-mg-T82105-Ab-1/ GM-Tg-mg-T82105-Ab-2 | Anti-Mouse CEACAM1 monoclonal antibody | Mouse |
GM-Tg-cynog-T82105-Ab-1/ GM-Tg-cynog-T82105-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CEACAM1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T82105-Ab-1/ GM-Tg-felg-T82105-Ab-2 | Anti-Feline CEACAM1 monoclonal antibody | Feline |
GM-Tg-cang-T82105-Ab-1/ GM-Tg-cang-T82105-Ab-2 | Anti-Canine CEACAM1 monoclonal antibody | Canine |
GM-Tg-bovg-T82105-Ab-1/ GM-Tg-bovg-T82105-Ab-2 | Anti-Bovine CEACAM1 monoclonal antibody | Bovine |
GM-Tg-equg-T82105-Ab-1/ GM-Tg-equg-T82105-Ab-2 | Anti-Equine CEACAM1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T82105-Ab-1/ GM-Tg-hg-T82105-Ab-2; GM-Tg-rg-T82105-Ab-1/ GM-Tg-rg-T82105-Ab-2; GM-Tg-mg-T82105-Ab-1/ GM-Tg-mg-T82105-Ab-2; GM-Tg-cynog-T82105-Ab-1/ GM-Tg-cynog-T82105-Ab-2; GM-Tg-felg-T82105-Ab-1/ GM-Tg-felg-T82105-Ab-2; GM-Tg-cang-T82105-Ab-1/ GM-Tg-cang-T82105-Ab-2; GM-Tg-bovg-T82105-Ab-1/ GM-Tg-bovg-T82105-Ab-2; GM-Tg-equg-T82105-Ab-1/ GM-Tg-equg-T82105-Ab-2 |
Products Name | Anti-CEACAM1 monoclonal antibody |
Format | mab |
Target Name | CEACAM1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CEACAM1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CEAM1/ CEACAM1/ BGP VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP001378 | human CEACAM1 Lentivirus plasmid |
ORF Viral Vector | vGMLP001378 | human CEACAM1 Lentivirus particle |
Target information
Target ID | GM-T82105 |
Target Name | CEACAM1 |
Gene ID | 634,708200,101086271 |
Gene Symbol and Synonyms | BGP,BGP1,BGPI,CEACAM1 |
Uniprot Accession | P13688 |
Uniprot Entry Name | CEAM1_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Prostate Cancer, Non-small cell lung carcinoma |
Gene Ensembl | ENSG00000079385 |
Target Classification | Checkpoint-Immuno Oncology |
The target: CEACAM1, gene name: CEACAM1, also named as BGP, BGP1, BGPI. This gene encodes a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. The encoded protein was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined. [provided by RefSeq, May 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.